Daridorexant and Driving: The First-Night and Fourth-Night Results

Before starting daridorexant (Quviviq), discuss next-morning driving with the prescriber. Its US label cautions about activities requiring full alertness.¹

What the simulator trial tested

The 2022 crossover study² randomized 60 healthy sleepers aged 50–79, including 30 women. Participants received daridorexant 50 mg or 100 mg, placebo and an active control in separate treatment periods. Driving was tested nine hours after dosing, after the first and fourth treatment nights.²

The main measure was variation in lateral lane position, a measure of weaving. With 50 mg, the adjusted average increase relative to placebo was 2.19 cm after the first dose and 0.26 cm after four consecutive nights. The corresponding 97.5% confidence intervals were 0.46–3.93 cm and −1.08–1.59 cm.²

Idorsia funded the study, and company employees helped design and analyze it. Participants were healthy sleepers, not people being treated for insomnia. A simulator outcome does not directly measure road-crash rates.²

Why four nights do not establish driving fitness

The current US label states that some participants still had impaired driving after four consecutive treatment nights, even though the average difference from placebo was no longer statistically significant. It emphasizes variation in individual sensitivity.¹

That distinction matters when reading “no significant effect.” A group result cannot tell a prescriber that a particular patient is unimpaired. It also cannot supply a rule that everyone may drive after four nights, after nine hours or after any other fixed interval drawn from this experiment.

The 100 mg research dose is twice the US maximum recommended nightly dose of 50 mg. It is not a dose to try. The US instructions specify at least seven hours before planned awakening; allowing that interval does not cancel the next-day warning.¹

Feeling awake is not the only check

MedlinePlus³ warns that driving may be impaired even when you feel fully awake. It advises no driving, machinery or dangerous activity within seven hours of taking daridorexant and until fully awake, with a clinician discussion about driving risks. Those are minimum precautions, not proof that driving becomes safe at the seven-hour mark.³

Bring a complete list of prescriptions, nonprescription medicines and supplements to that discussion. MedlinePlus³ also says never to take more than one dose per day, even if sleep remains difficult, and not to drink alcohol while taking it.³

Make the morning plan specific

Tell the prescriber when you normally take evening medicines, when you must get up and what the morning requires. Include the school run, a highway commute, machinery or another task where reduced alertness would matter. Ask how the prescription instructions fit those responsibilities and what to do if the planned sleep opportunity changes.

Chapter 10’s “Medicines Belong in Shared Decisions” in Did I Do That in My Sleep? places next-day impairment, interactions and the review plan alongside expected sleep benefit. Our orexin-blocking sleep-pill comparison covers the wider label differences among these medicines.

Sleep-driving is a separate warning from impaired morning driving. If complex sleep behavior occurs, the Quviviq label directs immediate discontinuation; contact the prescriber right away.¹ Do not use a morning alertness note, an uneventful short trip or a phone reaction-time exercise as a substitute for the prescribing discussion.